StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Specialty Care Portfolio Total [legacy] by Quarter

Specialty Care Portfolio Total [legacy] — International ($M) ($M)

QuarterlyAnnual

Pfizer Specialty Care Portfolio Total [legacy]: $2,614M in Q4 2025, up 10.8% from a year earlier. That is the highest of the 18 quarters on record here.

Latest, Q4 2025
2,614
Period ended Dec 31, 2025
Change on a year earlier
+10.8%
2,359 in Q4 2024
History
18 quarters
Since Q3 2021
Sources
14
Documents cited below

Where the Q4 2025 figure comes from

“|| Specialty Care | $ | 4,771 | $ | 4,438 | 8% | 6% | $ | 2,157 | $ | 2,079 | 4% | $ | 2,614 | $ | 2,359 | 11% | 8%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSpecialty Care Portfolio Total [legacy] — International ($M) ($M)Year on yearSource
Q4 2025Dec 31, 20252,614+10.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 20252,257+6.6%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 20252,293+8.7%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 20252,0850.0%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 20242,359+8.3%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 20242,118+5.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 20242,110+3.5%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 20242,084-2.8%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20232,178+8.2%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20232,011+4.9%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20232,038+1.1%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 20232,143-3.9%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 20222,013-12.1%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 20221,917-14.0%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 20222,015–Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 20222,229–Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗

Cite this data

StockData. (2026). Pfizer Specialty Care Portfolio Total [legacy] ($M), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-sc-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.